Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2013 Nov;62(11):3669-70.
doi: 10.2337/db13-1207.

Depleting T cells in newly diagnosed autoimmune (type 1) diabetes--are we getting anywhere?

Åke Lernmark  1
Affiliations
Comment

Depleting T cells in newly diagnosed autoimmune (type 1) diabetes--are we getting anywhere?

Åke Lernmark. Diabetes. 2013 Nov.
No abstract available

PubMed Disclaimer

Figures

FIG. 1.
FIG. 1.
Relationship between insulin release in relation to the remaining β-cell mass. Research subjects entering an intervention trial at 8–35 years of age at the time of clinical diagnosis, such as the Protégé trial, may have vastly different baselines that may affect treatment and outcome. Subjects to the left may have lost a major proportion of their β-cells but still remain asymptomatic due to well-functioning β-cells and high insulin sensitivity. Subjects to the right may develop diabetes due to poor β-cell function and high insulin resistance. Heterogeneity already at baseline complicates immunomodulation intervention trials in T1D. The figure is courtesy of Daniel Cook and Ian Sweet, University of Washington, Seattle, Washington.
See this image and copyright information in PMC

Comment on

References

    1. Leslie RD, Kolb H, Schloot NC, et al. Diabetes classification: grey zones, sound and smoke: Action LADA 1. Diabetes Metab Res Rev 2008;24:511–519 - PubMed
    1. Atkinson MA, Eisenbarth GS, Michels AW. Type 1 diabetes. Lancet. 25 July 2013 [Epub ahead of print] - PMC - PubMed
    1. Shakespeare W, Romeo and Juliet, John Danter, 1597
    1. Hagopian W, Ferry RJ, Jr, Sherry N, et al. for the Protégé Trial Investigators Teplizumab preserves C-peptide in recent-onset type 1 diabetes: two-year results from the randomized, placebo-controlled Protégé trial. Diabetes 2013;62:3901–3908 - PMC - PubMed
    1. Herold KC, Gitelman SE, Ehlers MR, et al. the AbATE Study Team Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders. Diabetes 2013;62:3766–3774 - PMC - PubMed

MeSH terms